Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
2011
A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
2008
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Cancer statistics, 2024
2024 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Targeting the mTOR signaling network in cancer
2007
An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations
2017
Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry
2002 Standout
Thirty-Day Mortality After Primary Cytoreductive Surgery for Advanced Ovarian Cancer in the Elderly
2011
Ovarian cancer
2014 Standout
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
2009 Standout
Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology
1999
mTOR inhibitors in the treatment of cancer
2008
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 Standout
Gestational trophoblastic disease
2010 Standout
mTOR signaling and drug development in cancer
2010
Mammalian target of rapamycin as a therapeutic target in oncology
2008
Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer?
2008
Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer
2016
Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer
2005
Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: A systematic review
2009
ESMO-Magnitude of Clinical Benefit Scale version 1.1
2017
The expanding universe of hypoxia
2008 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Influence of Department Volume on Survival for Ovarian Cancer: Results From a Prospective Quality Assurance Program of the Austrian Association for Gynecologic Oncology
2009
Impact of quality of care on racial disparities in survival for endometrial cancer
2020
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
2013 Standout
Ovarian cancer: Patterns of surgical care across the United States
2006
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
2011
A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK
2002
Malignant Gliomas in Adults
2008 Standout
Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents
2015 Standout
Combination chemotherapy for high-risk gestational trophoblastic tumour
2009
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Specialized Care and Survival of Ovarian Cancer Patients in The Netherlands: Nationwide Cohort Study
2008
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Use of chemotherapy during human pregnancy
2004
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review
2008
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Cervical cancer
2019 Standout
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Scope and Impact of Financial Conflicts of Interest in Biomedical Research
2003 Standout
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
2003 Standout
Predictors of comprehensive surgical treatment in patients with ovarian cancer
2007
How Many Cancer Patients Use Complementary and Alternative Medicine
2011 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
2010
The Pharmacology of mTOR Inhibition
2009 Standout
2015
Ovarian cancer statistics, 2018
2018 Standout
Combination chemotherapy for high-risk gestational trophoblastic tumour
2006
Remedies and life changes among invasive cervical cancer survivors.
2007
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensitymatched analysis
2016
Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study
2005 Standout
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation
2013
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
2014 Standout
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
2009
The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy
2007
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Recommendation Statement.
2015
Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries
2023
First-line chemotherapy in low-risk gestational trophoblastic neoplasia
2016
Works of L. Elit being referenced
Outcomes in Surgery for Ovarian Cancer
2002
An Endodermal Sinus Tumor Diagnosed in Pregnancy: Case Report and Review of the Literature
1999
Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
1997
Prophylactic oophorectomy in Ontario
2001
Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer
2001
Follow-Up for Women after Treatment for Cervical Cancer
2010
High-Dose Methotrexate for Gestational Trophoblastic Disease
1994
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
2013
Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study
2020
A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
2008
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.
2010
Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer—NCIC IND 160
2006
The impact of prophylactic salpingo‐oophorectomy on quality of life and psychological distress in women with a BRCA mutation
2011
Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial
2006
Impact of Wait Times on Survival for Women With Uterine Cancer
2013